跳至主要内容
临床试验/EUCTR2015-001235-20-GB
EUCTR2015-001235-20-GB进行中(未招募)1 期

Perfusion by Arterial Spin labelling following Single dose Tadalafil In Small vessel disease - PASTIS

St George's University of London0 个研究点目标入组 90 人开始时间: 2015年5月13日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
90

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • 1. Radiological evidence of cerebral small vessel disease defined as: MRI evidence of lacunar infarct(s) (= 1.5 cm maximum diameter) and/or confluent deep white matter leukoaraiosis (= grade 2 on Fazekas scale)
  • 2. Clinical evidence of cerebral small vessel disease can be:
  • a) lacunar stroke syndrome with symptoms lasting >24 hours, occurring at least 6 months previously; OR:
  • b) transient ischaemic attack lasting < 24 hours with limb weakness, hemi-sensory loss or dysarthria at least 6 months previously AND with MRI DWI performed acutely showing lacunar infarction, OR if MRI is not performed within 10 days of TIA, a lacunar infarction in an anatomically appropriate position is demonstrated on a subsequent MRI
  • 3. Age = 55 years.
  • 4. Imaging of the carotid arteries with Doppler ultrasound, CT
  • angiography or MR angiography in the previous 12 months,
  • demonstrating < 70% stenosis in both internal carotid arteries
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 20
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 34

排除标准

  • 1. Known diagnosis of dementia
  • 2. Cortical infarction (>1.5 cm maximum diameter)
  • 3. Systolic BP <90 and/or diastolic BP < 50
  • 4. Creatinine Clearance<50ml/min
  • 5. Severe hepatic impairment
  • 6. History of Lactose intolerance
  • 7. Concomitant use of PDE5 inhibitors e.g. sildenafil, tadalafil, vardenafil.
  • 8. Concomitant use of alpha-blockers e.g. alfuzosin, doxazosin, indoramin, prazosin, tamsulosin, and terazosin can all increase the risk of postural hypotension.
  • 9.Participants receiving nicorandil and nitrates e.g. isosorbide mononitrate, isosorbide dinitrate, glyceryl trinitrate
  • 10. weight > 130kg
  • 11 Uncontrolled cardiac failure
  • 12. Persistent or paroxysmal atrial fibrillation
  • 13. History of gastric ulceration
  • 14. History of ‘sick sinus syndrome’ or other supraventricular cardiac conduction conditions such as sinoatrial or atrioventricular block
  • 15. Uncontrolled COPD
  • 16. Stroke or TIA within the last 6 months
  • 17. MRI not tolerated or contra-indicated : MRI exclusion criteria -Participant has a cardiac pacemaker; recent surgery; vascular clips; metal implants or joint replacements; have had metal fragments in their eyes; has ever worked on a lathe; has shrapnel from a war injury; possibility of pregnancy
  • 18. Known monogenic causes of stroke e.g.. CADASIL
  • 19 Unable to provide informed consent
  • 20. enrolled in another CTIMP study.

研究者

相似试验